Bernhard Schaefer

机构：Bayer (Germany) · ORCID：0009-0009-1305-4415

发表论文 18 篇 · 总被引 147 次 · h-index 8

代表论文

• Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK (2019 · BMJ Open · 被引 50)
• Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism (2023 · JACC CardioOncology · 被引 21)
• Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low-Molecular-Weight Heparin: The OSCAR-UK Study (2024 · Thrombosis and Haemostasis · 被引 12)
• Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding (2023 · TH Open · 被引 11)
• Patient Preferences for Nonvitamin K Antagonist Oral Anticoagulants in Stroke Prevention: A Multicountry Discrete Choice Experiment (2019 · Cardiology Research and Practice · 被引 11)
• Worsening of kidney function in patients with atrial fibrillation and chronic kidney disease: evidence from the real-world CALLIPER study (2022 · Current Medical Research and Opinion · 被引 10)